Skip to main content

Table 1 Clinical and demographic features of patients included in the study

From: Improved gut microbiota features after the resolution of SARS‑CoV‑2 infection

  SARS-CoV2  +  (31) SARS-CoV2 − (18) p value
Age 66.7  ±  14.4 67.1  ±  17.5 0.372
Sex
 Males 23 (74.2%) 11 (61.1%) 0.357
 Females 8 (25.8%) 7 (38.9%)
Gastrointestinal symptoms 13 (41.9%) 5 (27.8%) 0.249
Respiratory failure* 22 (73.3%) 6 (33.3%) 0.012
ARDS categoriesa
 III 14 (63.6%) 5 (83.3%)  
 II 7 (31.8%) 1 (16.7%)  
 I 1 (4.5%) 0  
History of chronic lung disease 4 (12.9%) 3 (16.7%) 0.512
Treatment during hospitalization
 Antibiotics 22 (71%) 18 (94.7%) 0.05
 Antivirals 27 (90%) 3 (16.7%) 0.00
 Hydroxychloroquine 29 (93.5%) 2 (10.5%) 0.017
Anti-IL-6 receptor monoclonal antibodies 8 (25.8%) 0  
  1. Numeric variables are reported as mean  ±  standard deviation, categorical ones as frequencies and percentages
  2. *Number of patients with respiratory failure during hospitalization (PaO2/FiO2 ratio  <  300)
  3. Significance was evaluated by Wilcoxon signed rank test and chi-square test (IBM SPSS Statistics)
  4. SARS‑CoV‑2 severe acute respiratory syndrome coronavirus 2; IL interleukin
  5. aIII PaO2/FiO2 ratio 200–300, II PaO2/FiO2 ratio 100–200, I PaO2/FiO2 ratio  <  100